BioCentury | Feb 4, 2021
Finance

Muted reception for Sensei, Landos on NASDAQ as more biotechs set to leap into public markets

...said the treatment showed a positive trend toward remission rates vs. placebo.Sensei’s underwriters are Citigroup, Piper Sandler...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...iTeos’ are J.P. Morgan, SVB Leerink, Piper Sandler and Wedbush PacGrow. Inozyme’s are BofA Securities, Cowen, Piper Sandler...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...a temporary intraday halt during the day ahead of NASDAQ trading. Poseida’s were BofA Securities, Piper Sandler...
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

...bioVenture Partners, Sofinnova Investments, RA Capital, Novartis Bioventures and Fidelity. Underwriters are BofA Securities, Cowen, Piper Sandler...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...The deal valued Repare at $701.2 million. Underwriters are Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler...
...of its $14-$16 range, raising $100 million for a valuation of $677.5 million. Underwriters are Piper Sandler...
BioCentury | Jun 16, 2020
Finance

June 15 Quick Takes: RA makes $200M investment in Novavax; plus venture rounds for Shattuck, ImmVira, Glyscend and Shukun

...Investors, Fidelity, EcoR1 Capital, Hatteras Venture Partners, Avidity Partners, Partner Fund Management, Emerson Collective and Piper Sandler...
BioCentury | Jun 3, 2020
Finance

Third Rock-launched Pliant is latest biotech to climb on public debut

...Lantern Pharma Inc. and Applied Molecular Transport Inc. (see “IPO Queue Grows” ). Citigroup, Cowen, Piper Sandler...
...Pliant’s deal. Targets CD51 (CD29) - Integrin α(V)β(1) Danielle Kopke, Staff Writer PLN-1474 PLN-74809 Pliant Therapeutics Inc. Novartis AG Third Rock Ventures Citigroup Cowen Piper Sandler Needham Integrin...
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

...now part of AbbVie Inc. (NYSE:ABBV), following its acquisition of Tobira Therapeutics Inc. Citigroup, Cowen, Piper Sandler...
BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

...a board seat, while OrbiMed has 8.5% (see “Arkin Ramping Up” ). Jefferies, SVB Leerink, Piper Sandler...
Items per page:
1 - 9 of 9
BioCentury | Feb 4, 2021
Finance

Muted reception for Sensei, Landos on NASDAQ as more biotechs set to leap into public markets

...said the treatment showed a positive trend toward remission rates vs. placebo.Sensei’s underwriters are Citigroup, Piper Sandler...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...iTeos’ are J.P. Morgan, SVB Leerink, Piper Sandler and Wedbush PacGrow. Inozyme’s are BofA Securities, Cowen, Piper Sandler...
BioCentury | Jul 10, 2020
Finance

Nkarta’s $252M IPO among biggest preclinical listings ever

...a temporary intraday halt during the day ahead of NASDAQ trading. Poseida’s were BofA Securities, Piper Sandler...
BioCentury | Jun 26, 2020
Finance

Akouos’ first-day pop outshines peers among NASDAQ IPO trio

...bioVenture Partners, Sofinnova Investments, RA Capital, Novartis Bioventures and Fidelity. Underwriters are BofA Securities, Cowen, Piper Sandler...
BioCentury | Jun 20, 2020
Finance

Forma, Repare shine in first-day performances as biotech IPOs on NASDAQ maintain momentum

...The deal valued Repare at $701.2 million. Underwriters are Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler...
...of its $14-$16 range, raising $100 million for a valuation of $677.5 million. Underwriters are Piper Sandler...
BioCentury | Jun 16, 2020
Finance

June 15 Quick Takes: RA makes $200M investment in Novavax; plus venture rounds for Shattuck, ImmVira, Glyscend and Shukun

...Investors, Fidelity, EcoR1 Capital, Hatteras Venture Partners, Avidity Partners, Partner Fund Management, Emerson Collective and Piper Sandler...
BioCentury | Jun 3, 2020
Finance

Third Rock-launched Pliant is latest biotech to climb on public debut

...Lantern Pharma Inc. and Applied Molecular Transport Inc. (see “IPO Queue Grows” ). Citigroup, Cowen, Piper Sandler...
...Pliant’s deal. Targets CD51 (CD29) - Integrin α(V)β(1) Danielle Kopke, Staff Writer PLN-1474 PLN-74809 Pliant Therapeutics Inc. Novartis AG Third Rock Ventures Citigroup Cowen Piper Sandler Needham Integrin...
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

...now part of AbbVie Inc. (NYSE:ABBV), following its acquisition of Tobira Therapeutics Inc. Citigroup, Cowen, Piper Sandler...
BioCentury | Mar 17, 2020
Finance

With strengthened balance sheet, Keros is latest biotech looking to test IPO market

...a board seat, while OrbiMed has 8.5% (see “Arkin Ramping Up” ). Jefferies, SVB Leerink, Piper Sandler...
Items per page:
1 - 9 of 9